The Emperor Has No Symptoms: The Risks of a Blanket Approach to Using Epinephrine Autoinjectors for All Allergic Reactions

November–December, 2016Volume 4, Issue 6, Pages 1143–1146

Paul J. Turner, FRACP, PhDPress enter key for correspondence informationPress enter key to Email the author

, 

Audrey DunnGalvin, PhD

, 

Jonathan O'B. Hourihane, MD, DM

Open Access

DOI: http://dx.doi.org/10.1016/j.jaip.2016.05.005

 |

Article Info

• Abstract

• Full Text

• Images
• References

Article Outline

1. Can Using Epinephrine Autoinjectors for Mild Allergic Symptoms Cause Harm?
2. Conclusions
3. References

Fatal anaphylaxis in humans is rare and unpredictable. We note a trend to provide allergic individuals with care plans that recommend immediate use of epinephrine autoinjectors if allergen ingestion is suspected, even in the absence of any allergic symptoms, without any supporting evidence base. Instructions to use an autoinjector device, irrespective of reaction severity and especially when symptoms are actually absent, are likely to add to parental and patient anxiety.

A multi-strain Synbiotic may reduce viral respiratory infections in asthmatic children: a randomized controlled trial

• Electron Physician
• v.8(9); 2016 Sep
• PMC5074739

Electron Physician. 2016 Sep; 8(9): 2833–2839.

Published online 2016 Sep 20. doi:  10.19082/2833

PMCID: PMC5074739

Hamid Ahanchian,1,2 Seyed Ali Jafari,3 Elham Ansari,4 Toktam Ganji,5 Mohammad Ali Kiani,3 Maryam Khalesi,5 Tooba Momen,6 and Hamidreza Kianifar3

Author information ► Article notes ► Copyright and License information ►

Abstract

Background and objective

Asthma is a growing problem worldwide. Acute exacerbations impose considerable morbidity, mortality, and increased cost. Viral respiratory infections are the most common cause (80–85%) of pediatric asthma exacerbations and admissions to the hospital. The aim of this study was to determine the effect of a new synbiotic Lactocare® on viral respiratory infections and asthma exacerbations in asthmatic children.

Increasing Comorbidities Suggest that Atopic Dermatitis Is a Systemic Disorder

Articles in Press

Patrick M. Brunner

, 

Jonathan I. Silverberg

, 

Emma Guttman-Yassky

, 

Amy S. PallerPress enter key for correspondence informationPress enter key to Email the author

, 

Kenji Kabashima

, 

Masayuki Amagai

, 

Thomas A. Luger

, 

Mette Deleuran

, 

Thomas Werfel

, 

Kilian Eyerich

, 

Georg Stingl

, Councilors of the International Eczema Council

corrected proof published online XXX

Open Access

Article Info

• Abstract

• Full Text
• References
• Supplemental Materials

Atopic dermatitis comorbidities extend well beyond the march to allergic conditions (food allergy, asthma, allergic rhinitis, allergic conjunctivitis, and eosinophilic esophagitis), suggesting both cutaneous and systemic immune activation. In reviewing atopic dermatitis comorbidities, Councilors of the International Eczema Council found a strong pattern of immune activation in peripheral blood and the propensity to both skin and systemic infections.

Specific Antibodies for the Detection of Alternaria Allergens and the Identification of Cross-Reactive Antigens in Other Fungi

Int Arch Allergy Immunol 2016;170:269-278

(DOI:10.1159/000449415)

Open Access

Twaroch T.E.a · Curin M.a · Sterflinger K.b · Focke-Tejkl M.a · Swoboda I.a ·Valenta R.a

aChristian Doppler Laboratory for Allergy Research, Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, and bDepartment for Biotechnology, University of Natural Resources and Applied Life Sciences, Vienna, Austria

Abstract:

Background: The mould Alternaria alternata is an important source of respiratory allergens. A. alternata extracts show great variations regarding allergenic potency. The aim of this study was to generate antibody probes specific for important Alternaria allergens and to use them to study allergen expression, depending on different culture conditions, as well as to search for cross-reactive allergens in other mould species. Methods: Synthetic peptides from antigenic regions of A. alternataallergens (Alt a 1, Alt a 2, Alt a 3, Alt a 6 and Alt a 8) were used to raise highly specific rabbit antibodies.

Effect of educational and electronic medical record interventions on food allergy management

• Allergy Asthma Proc
• PMC5013233

Allergy and Asthma Proceedings

Allergy Asthma Proc. 2016 Sep-Oct; 37(5): 404–408.

doi:  10.2500/aap.2016.37.3970

PMCID: PMC5013233

Ari Zelig, M.D.,1 Ilana Harwayne-Gidansky, M.D.,2 Allison Gault, M.D.,3 and Julie Wang, M.D.3

Author information ► Copyright and License information ►

Abstract

Background:

The growing prevalence of food allergies indicates a responsibility among primary care providers to ensure that their patients receive accurate diagnosis and management.

Late‐Onset Asthma Predicts Cardiovascular Disease Events: The Wisconsin Sleep Cohort

• 
   Am Heart Assoc. 2016; 5: e003448doi: 10.1161/JAHA.116.003448
• Original Research - Epidemiology

1. Matthew C. Tattersall, DO, MS¹; 
2. Jodi H. Barnet, MS²; 
3. Claudia E. Korcarz, DVM¹;
4. Erika W. Hagen, PhD²; 
5. Paul E. Peppard, PhD²; 
6. James H. Stein, MD, FAHA*,¹

+Author Affiliations

1. ¹Division of Cardiovascular Medicine, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI
2. ²Department of Population Health, University of Wisconsin School of Medicine and Public Health, Madison, WI

Abstract

Background Asthma is a heterogeneous syndrome with different clinical subtypes that is associated with an increased risk for cardiovascular disease (CVD). We hypothesized that the late‐onset subtype of asthma is associated with a higher risk of incident CVD.

Urine metabolome profiling of immune-mediated inflammatory diseases

BMC Medicine

RESEARCH ARTICLE

 

OPEN ACCESS

 

OPEN PEER REVIEW

• Arnald Alonso,
• Antonio JuliàEmail authorView ORCID ID profile,
• Maria Vinaixa,
• Eugeni Domènech,
• Antonio Fernández-Nebro,
• Juan D. Cañete,
• Carlos Ferrándiz,
• Jesús Tornero,
• Javier P. Gisbert,
• Pilar Nos,
• Ana Gutiérrez Casbas,
• Lluís Puig,
• Isidoro González-Álvaro,
• José A. Pinto-Tasende,
• Ricardo Blanco,
• Miguel A. Rodríguez,
• Antoni Beltran,
• Xavier Correig,
• Sara MarsalEmail author and
• for the IMID Consortium

BMC Medicine201614:133

DOI: 10.1186/s12916-016-0681-8

©  The Author(s). 2016

Open Peer Review reports

Abstract

Background

Immune-mediated inflammatory diseases (IMIDs) are a group of complex and prevalent diseases where disease diagnostic and activity monitoring is highly challenging. The determination of the metabolite profiles of biological samples is becoming a powerful approach to identify new biomarkers of clinical utility. In order to identify new metabolite biomarkers of diagnosis and disease activity, we have performed the first large-scale profiling of the urine metabolome of the six most prevalent IMIDs: rheumatoid arthritis, psoriatic arthritis, psoriasis, systemic lupus erythematosus, Crohn’s disease, and ulcerative colitis.

Applicability of predictive toxicology methods for monoclonal antibody therapeutics: status Quo and scope

Open Access  Review Article 

Arch Toxicol (2016). doi:10.1007/s00204-016-1876-7

• Arathi KizhedathEmail author
• Simon Wilkinson
• Jarka Glassey

Abstract

Biopharmaceuticals, monoclonal antibody (mAb)-based therapeutics in particular, have positively impacted millions of lives. MAbs and related therapeutics are highly desirable from a biopharmaceutical perspective as they are highly target specific and well tolerated within the human system. Nevertheless, several mAbs have been discontinued or withdrawn based either on their inability to demonstrate efficacy and/or due to adverse effects.